FN1 and chronic myelogenous leukemia, BCR-ABL1 positive: Intravenous administration of fibronectin also significantly prolonged the survival of mice with BCR-ABL1T315I+ CML (P = 0.017; Fig. 6c) and increased fibronectin levels in the BM (Fig. S7A).